BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.
BioCryst Pharmaceuticals, Inc.
Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure
To learn more about BioCryst Pharmaceuticals please read the company’s 2012 10K annual report.
BioCryst has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has two early-stage programs: BCX4161 and a 2nd generation oral inhibitor of plasma kallikrein for hereditary angioedema, and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.
Latest News
May 9, 2013BioCryst to Present at Two Upcoming Investor Conferences
May 7, 2013BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results
April 23, 2013BioCryst to Announce First Quarter 2013 Financial Results May 7
UPCOMING EVENTS
BioCryst First Quarter Results, Corporate Update May 7, 2013--webcast & conference call at 11:00 AM ET